1) 深 澤 万 左 友 ， 住 田 能 弘 ， 多 田 央 子 ， 他 ： Meropenemの細菌学的評価。Chemotherapy 40 (suppl. 1): 7489, 1992
2) 山 口 惠 三 ， 石 井 良 和 ， 岩 田 守 弘 ， 他 ：
Meropenemを含む各種注射用抗菌薬に対す
る2002年臨床分離株の感受性サーベイラン ス。Jpn. J. Antibiotics 57: 70104, 2004 3) 山 口 惠 三 ， 石 井 良 和 ， 岩 田 守 弘 ， 他 ：
Meropenemを含む各種注射用抗菌薬に対す
る2004年臨床分離株の感受性サーベイラン ス。Jpn. J. Antibiotics 58: 655689, 2005 4) 山 口 惠 三 ， 石 井 良 和 ， 岩 田 守 弘 ， 他 ：
Meropenemを含む各種注射用抗菌薬に対す
る2006年臨床分離株の感受性サーベイラン ス。Jpn. J. Antibiotics 60: 344377, 2007 5) 井上 薫：Meropenemのラットおよびサル
に お け る 腎 毒 性 試 験 。Chemotherapy 40 (suppl. 1): 222237, 1992
6) 成人院内肺炎診療ガイドライン。日本呼吸器 学会呼吸器感染症に関するガイドライン作成 委員会編，杏林社，東京，2008
7) 細菌性髄膜炎の診療ガイドライン。細菌性髄 膜炎の診療ガイドライン作成委員会編，医学 書院，東京，2007
8) LIVERMORE, D. M. & N. WOODFORD: The b-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14: 213220, 2006
9) 石井良和：基質異性拡張型bラクタマーゼ産 生菌の基礎。医学のあゆみ221: 503506, 2007
10) National Committee for Clinical Laboratory Standards: Performance standards for antimi-crobial susceptibility testing; Fourteenth in-formational supplement (NCCLS M100-S14), 2004
11) National Committee for Clinical Laboratory Standards: Performance standards for antimi-crobial susceptibility testing; Nineteenth informational supplement (CLSI M100-S19), 2009
12) 生方公子，千葉菜穂子，中山信子，他：薬剤 耐性機構からみたb-ラクタマーゼ非産生アン ピシリン耐性インフルエンザ菌(BLNAR) の 特 徴 。 日 本 臨 床 微 生 物 学 雑 誌 9: 2229, 1999
13) National Committee for Clinical Laboratory Standards: Methods for dilution antimicro-bial susceptibility tests for bacteria that grow aerobically; Approved standard—seventh edition (NCCLS M7-A6), 2003
14) National Committee for Clinical Laboratory Standards: Methods for antimicrobial suscep-tibility testing of anaerobic bacteria; Ap-proved standard—sixth edition (NCCLS M11-A6), 2004
15) National Committee for Clinical Laboratory Standards: Methods for dilution antimicro-bial susceptibility tests for bacteria that grow aerobically; Approved standard—seventh edition (CLSI M7-A7), 2006
16) National Committee for Clinical Laboratory Standards: Methods for antimicrobial suscep-tibility testing of anaerobic bacteria; Ap-proved standard—seventh edition (CLSI M11-A7), 2007
17) 五島瑳智子，武藤弓子，小川正俊：b-ラクタ マーゼ検出法。感染症13: 7383, 1983 18) PERILLI, M.; E. DELL’AMICO, B. SEGATORE, et
al.: Molecular characterization of extended-spectrum b-lactamases produced by nosoco-mial isolates of Enterobacteriaceae from an Italian nationwide survey. J. Clin. Microbiol.
40: 611614, 2002
19) STEWARD, C.D.; J. K. RASHEED, S. K. HUBERT, et al.: Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories
Antimicrob. Agents Chemother. 40: 509 513, 1996
21) SABATE, M.; R. TARRAGO, F. NAVARRO, et al.:
Cloning and sequence of the gene encoding a novel cefotaxime-hydrolyzing b-lactamase (CTX-M-9) from Escherichia coli in Spain.
Antimicrob. Agents Chemother. 44: 1970 1973, 2000
22) SENDA, K.; Y. ARAKAWA, K. NAKASHIMA, et al.: Multifocal outbreaks of metallo b -lactamase-producing Pseudomonas aerugi-nosa resistant to broad-spectrum b-lactams, including carbapenems. Antimicrob. Agents Chemother. 40: 349353, 1996
23) POIREL, L.; T. NAAS, D. NICOLAS, et al.: Char-acterization of VIM-2, a carbapenem-hydrolyzing metallo-b-lactamase and its plas-mid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother. 44:
891897, 2000
24) SAITO, A.; T. INAMATSU, J. OKADA, et al.: Clini-cal breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supple-mental information for some agents already released. J. Infect. Chemother. 5: 223226, 1999
25) 門田淳一，石井良和，草地信也，他：抗菌薬 ブレイクポイント委員会報告―呼吸器感染症，
敗血症および尿路感染症におけるブレイクポ イント：新規抗菌薬の追加（2009年）。日本 化学療法学会雑誌57: 343345, 2009 26) 吉田早苗，古賀哲文， 角田正代，他：2006
年臨床分離株に対するpanipenemの抗菌力。
Jpn. J. Antibiotics 61: 117, 2008
27) REYNOLDS, R.; N. POTZ, M. COLMAN, et al.:
crobial surveillance program (1998-2004).
Diagn. Microbiol. Infect. Dis. 56: 6368, 2006
29) PASCUALA, A.; E. PEREAA, M. ALVAREZ, et al.: The meropenem yearly susceptibility test information collection antimicrobial sus-ceptibility program in Spain: a 5-year analy-sis. Diagn. Microbiol. Infect. Dis. 57: 195 200, 2007
30) PATZER, J. A.; D. DZIERZANOWSKA & P. J.
TURNER: Trends in antimicrobial susceptibil-ity of Gram-negative isolates from a paedi-atric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007).
J. Antimicrob. Chemother. 62: 369375, 2008
31) 山口惠三，大野 章，石井良和，他：2007 年に全国72施設から分離された臨床分離株
12,919株の各種抗菌薬に対する感受性サーベ
イランス。Jpn. J. Antibiotics 62: 346370, 2009
32) 小林芳夫，墨谷祐子，上遠野保裕：2008年 に分離された血液由来菌に対するmeropenem の抗菌力。Jpn. J. Antibiotics 62: 492501, 2009
33) SUZUKI, S.; N. SHIBATA, K. YAMANE, et al.:
Change in the prevalence of extended-spectrum-b-lactamase-producing E. coli in Japan by clonal spread. Antimicrob. Agents Chemother. 63: 7279, 2009
34) CHONG, Y.; H. YAKUSHIJI, Y. ITO, et al.: Ce-fepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hemato-logical malignancies. Int. J. Infect. Dis.
E171E175, 2010
35) TRECARICHI, E. M.; M. TUMBARELLO, T.
extended-spectrum-b-lactamase (ESBL) pro-duction and fluoroquinolone resistance in bloodstream infections caused by Esche-richia coli in patients with hematological malignancies. J. Infect. 58: 299307, 2009 36) SCHWABER, M. J. & Y. CARMELI: Mortality and
delay in effective therapy associated with extended-spectrum b-lactamase production in Enterobacteriaceae bacteraemia: a system-atic review and meta-analysis. J. Antimicrob.
Chemother. 60: 913920, 2007
37) NIKI, Y.; H. HANAKI, M. YAGISAWA, et al.: The first nationwide surveillance of bacterial res-piratory pathogens conducted by the Japan-ese Society of Chemotherapy. Part 1: a gen-eral view of antibacterial susceptibility. J.
Infect. Chemother. 14: 279290, 2008 38) 吉田 勇，木村美司，東山伊佐夫，他：各種
抗菌薬に対する臨床分離株の感受性サーベイ ランス―2000年分離グラム陰性菌に対する 抗菌力―。日本化学療法学会雑誌51: 209 232, 2003
39) NIKI, Y.; H. HANAKI, T. MATSUMOTO, et al.:
Nationwide surveillance of bacterial respira-tory pathogens conducted by the Japanese
Society of Chemotherapy in 2007: general view of the pathogens antibacterial suscep-tibility. J. Infect. Chemother. 15: 156157, 2009
40) KIMURA, S.; J. ALBA, K. SHIROTO, et al.:
Clonal diversity of metallo-b -lactamase-pos-sessing Pseudomonas aeruginosa in geo-graphically diverse regions of Japan. J. Clin.
Microbiol. 43: 458461, 2005
41) RHOMBERG, P. R. & R. N. JONES: Summary trends for the meropenem yearly susceptibil-ity test information collection program: a 10-year experience in the United States. Diagn.
Microbiol. Infect. Dis. 65: 414426, 2009 42) 三國谷雄，加藤佳久，小林祐子，他：本邦に
おいて1990年から2006年の間に分離された methicillin-resistant Staphylococcus aureus の抗菌薬感受性の経年的変化。日本化学療法 学会雑誌57: 3739, 2009
43) 藤村亨滋，吉田 勇，伊藤喜久，他：各種抗 菌薬に対する2004年臨床分離好気性グラム 陽性球菌および嫌気性菌の感受性サーベイラ ンス。日本化学療法学会雑誌56: 543561, 2008
Department of Microbiology and Infectious Diseases, Toho University
School of Medicine
* Department of Laboratory Medicine, Toho University Omori Medical Center
NAOKIWATANABEand MASAAKISHINAGAWA Department of Clinical Laboratory
Medicine, Division of Laboratory Diagnosis, Sapporo Medical University
School of Medicine
MINORUYASUJIMA
Department of Laboratory Medicine, Hirosaki University Graduate
School of Medicine
AKIRASUWABEand MAKIKOKURODA* Department of Laboratory Medicine,
Iwate Medical University School of Medicine
* Department of Central Clinical Laboratories, Iwate Medical University
Hospital
MITSUOKAKUand MIHOKITAGAWA Department of Infection Control and
Laboratory Diagnostics, Tohoku University Graduate School of Medicine
KEIJIKANEMITSUand YUJIIMAFUKU
Department of Clinical Laboratory Medicine, Fukushima Medical University
MASAMIMURAKAMIand SACHIEYOMODA* Department of Clinical Laboratory Medicine, Gunma University Graduate
School of Medicine
* Clinical Laboratory Center,
TOSHIYUKIYAMADA Department of Clinical Laboratory Medicine, Jichi Medical University,
School of Medicine
FUMIONOMURA
Division of Laboratory Medicine, Chiba University Hospital
HARUSHIGEKANNO
Department of Internal Medicine, Takane Hospital
SHIGEFUMIMAESAKIand GIICHIHASHIKITA* Department of Infectious Disease &
Infection Control, Saitama Medical School
* Department of Laboratory Medicine, Saitama Medical School
SHIGEMIKONDOand SHIGEKIMISAWA* Department of Clinical Pathology, Juntendo University School of Medicine
* Department of Clinical Laboratory, Juntendo University Hospital
HAJIMEHORIUCHIand YOKOTAZAWA
Clinical Laboratory, NTT Medical Center, Tokyo
HIDEKINAKASHIMAand HIROMUTAKEMURA
Department of Microbiology, St. Marianna University School of Medicine
MASAHIKOOKADAand YOSHINORIHORIKAWA*
Division of Clinical Preventive Medicine, Niigata University
* Clinical Laboratory Division, Niigata
MASATOMAEKAWAand OSANORINAGURA* Department of Laboratory Medicine,
Hamamatsu University School of Medicine
* Hamamatsu University School of Medicine University Hospital, Clinical
Laboratory Department of Laboratory Medicine
TETSUYAYAGIand HISASHIBABA
Department of Infectious Diseases, Nagoya University Hospital
SHIOMIISHIGO
Clinical Laboratory, Ogaki Municipal Hospital
NAOHISAFUJITAand TOSHIAKIKOMORI* Department of Infection Control and Laboratory Medicine, Kyoto Prefectural
University of Medicine
* Department of Clinical Laboratory, Kyoto Prefectural University of Medicine
SATOSHIICHIYAMA
Department of Clinical Laboratory Medicine, Kyoto University Graduate
School of Medicine
KIYOHARUYAMANAKAand YOKOMURATA Division of Clinical Laboratory,
Otemae Hospital
SHUJIMATSUOand HISASHIKOHNO
Department of Clinical Pathology, Tenri Hospital
SEIJIKAWANOand SHOHIROKINOSHITA
Clinical Laboratory, Kobe University Hospital
TOMOHIKOTAMINATOand KIYOSHI
NEGAYAMA
Department of Clinical Laboratory, Kagawa University Hospital
MITSUHARUMURASEand HITOSHI
MIYAMOTO
Division of Medical Technology, Ehime University Hospital
NOBUCHIKAKUSANOand MOTOKONOSE Department of Central Clinical Laboratory, Okayama University Hospital
MICHIYAYOKOZAKIand HIDEYUKIITAHA* Division of Clinical Laboratory Medicine,
Hiroshima University Hospital
* Department of Clinical Laboratory Medicine, Hiroshima University Hospital
AKIRAMATSUNAGAand HISAEYOSHIMURA
Clinical Laboratory, Fukuoka University Hospital
SHIGERUKOHNO, KATSUNORI
YANAGIHARA* and JUNICHIMATSUDA* Second Department of Internal Medicine,
Nagasaki University Hospital
* Department of Laboratory Medicine, Nagasaki University Hospital
TETSUNORISAIKAWAand KAZUFUMI HIRAMATSU
Clinical Laboratory Center, Oita University Hospital
The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clini-cal isolates of 2655 strains including 810 strains of positive bacteria, 1635 strains of Gram-negative bacteria, and 210 strains of anaerobic bacteria obtained from 30 medical institutions during 2009 was examined. The results were as follows;
1. MEPM was more active than the other carbapenem antibiotics tested against Gram-nega-tive bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus(MRSA).